Results of an ongoing Phase 1 clinical trial indicate that the anti-cancer drug lorvotuzumab mertansine in combination with Revlimid-dexamethasone is active in relapsed/refractory multiple myeloma patients.

“There is encouraging activity observed at all dose levels,” said Dr. Jesus Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, who presented these findings at the 47^th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.

In a summary talk about potential new myeloma treatments, Dr. Nikhil Munshi from the Dana-Farber Cancer Institute said that he was encouraged by…

Yesterday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting in Chicago, and it was especially packed with presentations related to multiple myeloma.

There was a morning session where a total of eight research abstracts were presented and discussed.  Then, late in the afternoon, there was an education session focused on multiple myeloma, with several different presentations.

The presentations during the morning session were on three different topics: Revlimid (lenalidomide) and its potential link to secondary cancer; myeloma bone disease; and new drugs being developed…

The 47th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 3, through Tuesday, June 7, in Chicago.

More than 30,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. This year’s meeting will primarily focus on the theme of “Patients, Pathways, Progress.”

The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists over 40 myeloma-based abstracts.

The Myeloma Beacon…

The American Society of Hematology meeting swung into full gear yesterday. The day was full of invited talks and a poster session.

The morning kicked off with an education session in which attendees could learn about several myeloma-related topics.

The first presentation was by Dr. Ola Landgren from the National Cancer Institute and National Institutes of Health in Bethesda, Maryland. Dr. Landgren spoke about monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma, precursor diseases of multiple myeloma.

A study published by Dr. Landgren last year showed that all multiple myeloma…